oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Comparative Study of ERG Status Assessment on DNA, mRNA, and Protein Levels Using Unique Samples from a Swedish Biopsy Cohort
Orebro University Hospital. Department of Laboratory Medicine; Department of Urology.
Univ Hosp Bonn, Inst Pathol, Dept Prostate Canc Res, Bonn, Germany..
Department of Laboratory Medicine, University Hospital of Örebro, Örebro, Sweden; Department of Urology, University Hospital of Örebro, Örebro, Sweden.
Hol Gen Probe, San Diego, CA USA..
Show others and affiliations
2014 (English)In: Applied immunohistochemistry & molecular morphology (Print), ISSN 1541-2016, E-ISSN 1533-4058, Vol. 22, no 2, 136-141 p.Article in journal (Refereed) Published
Abstract [en]

The ERG rearrangement is identified in approximately 50% of prostate cancer screened cohorts and is known to be highly specific. This genetic aberration, most commonly leading to the TMPRSS2-ERG fusion, but also SLC45A3-ERG or NDRG1-ERG fusions, all leading to an overexpression of a truncated ERG protein. Most studies have applied in situ hybridization (FISH) methods or mRNA-based assays to investigate the ERG status. Recently, studies showed that ERG protein levels assessed by ERG antibodies can be used as a surrogate marker for ERG rearrangement. In the current study, we investigate ERG status on a series of diagnostic biopsies using DNA-based, mRNA-based, and protein-based assays. We formally compared 3 assay results (ie, FISH, fusion mRNA, and immunohistochemistry) to identify which method could be most appropriate to use when having limited amount of tissue. ERG rearrangement was found in 56% of the cases. Comparing ERG rearrangement status by FISH with ERG overexpression and TMPRSS2-ERG fusion transcript we found 95.1% (154/162, Fisher exact test 9.50E-36) and 85.2% (138/162, Fisher exact test 7.26E-22) concordance, respectively. We show that the ERG antibody highly correlates with the ERG rearrangement with high sensitivity and specificity. We also identified the most common TMPRSS2-ERG isoform in the majority of ERG rearranged cases. These results provide compelling evidence that the ERG antibody can be used to further investigate the role of ERG in prostate cancer.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2014. Vol. 22, no 2, 136-141 p.
Keyword [en]
prostate cancer, ERG, gene fusion
National Category
Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:oru:diva-56739DOI: 10.1097/PDM.0b013e31829e0484ISI: 000331540300008PubMedID: 24517914Scopus ID: 2-s2.0-84896712983OAI: oai:DiVA.org:oru-56739DiVA: diva2:1083959
Available from: 2017-03-23 Created: 2017-03-23 Last updated: 2017-03-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Svensson, Maria A.Helenius, GiselaAndersson, Swen-OlofDemichelis, FrancescaAndrén, OveRubin, Mark A.
By organisation
Orebro University Hospital
In the same journal
Applied immunohistochemistry & molecular morphology (Print)
Clinical Laboratory Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 54 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf